Compare · head to head
Gene One Life Science vs WuXi Biologics (Cayman)
WuXi Biologics (Cayman) ranks higher overall — 360 rank 87 vs 28.
WuXi Biologics (Cayman) leads on Value (52 vs 44) and Safety (68 vs 36). The two are close on Quality and Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | South Korea | Hong Kong SAR China |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Life Sciences Tools & Services |
| Size | X-Small | X-Large |
| ISIN | KR7011000007 | KYG970081173 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 28 | 87 |
| Value | 44 | 52 |
| Quality | 53 | 55 |
| Growth | NR | 70 |
| Safety | 36 | 68 |
| Sentiment | 44 | 45 |
| Quality details | ||
| Profitability | 52 | 67 |
| Cash Truth | 53 | 42 |
Gene One Life Science vs Towa PharmaceuticalGene One Life Science vs Mayne PharmaGene One Life Science vs Zai LabGene One Life Science vs Telix PharmaceuticalsAdd a third stock →
Full analyses: Gene One Life Science · WuXi Biologics (Cayman)
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100